QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module VI: Difficult ICSR Validity and Assessment Scenarios

Test your understanding of the concepts covered by GVP Module VI: Difficult ICSR Validity and Assessment Scenarios.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should quality control review both invalid and valid or borderline reports?

Because all reports must ultimately be processed as valid ICSRs Because errors can occur in both directions, including creating false-positive cases and failing to recognise valid cases Because invalid reports are more important than valid reports Because duplicate assessment is required only for rejected reports

Question 2 of 10 A medication-error report describes administration of the wrong dose but explicitly states that the patient experienced no clinical consequence. What is the best approach?

Automatically create an adverse reaction called medication error Assess it under the applicable special-situation or medication-error pathway without inventing a reaction Reject all medication-error information because it is outside pharmacovigilance Code the most likely toxicity associated with the incorrect dose

Question 3 of 10 A report states, "Someone reported that a patient had a reaction," but provides no information sufficient to identify the source. Which conclusion is most appropriate?

The reporter is identifiable because the report came through an established channel Reporter identifiability should be assessed and may require clarification or follow-up The patient automatically serves as the identifiable reporter The organisation should infer the reporter's identity from the product involved

Question 4 of 10 A product complaint also states that a patient was injured after using the defective product. What is the most appropriate organisational response?

Process only the quality complaint because the defect is the primary issue Process only the ICSR because quality information is not relevant to pharmacovigilance Coordinate quality and pharmacovigilance assessments while distinguishing the defect, exposure and clinical event Replace the injury with the product defect as the adverse reaction

Question 5 of 10 A vague source states only, "The patient experienced an adverse event." What should the processor do?

Replace the phrase with the most likely diagnosis based on the product's known risks Treat the phrase as sufficient evidence of a specific reaction such as nausea Assess whether the nonspecific statement satisfies the applicable criteria and seek clarification where possible Discard the report because nonspecific terms have no pharmacovigilance value

Question 6 of 10 A new report contains additional details that match an existing patient, product and event in the safety database. What is the principal processing concern?

Create a new case because every source must generate a separate case Perform a controlled duplicate assessment before creating or retaining a separate case Reject the new source because follow-up information cannot be used Replace the existing case with the new report without documenting the relationship

Question 7 of 10 During follow-up, a report initially understood as an isolated symptom is shown to concern a different diagnosis and medicinal product exposure. What is the appropriate response?

Append the new information without changing the prior assessment Reassess the case because new information may alter the clinical interpretation, product attribution or even indicate a duplicate Delete the original information to avoid inconsistency Retain the original reaction because initial coding cannot be revised

Question 8 of 10 Which combination represents the four minimum elements required for a valid ICSR under the framework described?

An identifiable reporter, an identifiable patient, a suspected medicinal product and a suspected adverse reaction A serious outcome, a hospital admission, a product complaint and a known causality assessment A patient, a product, a laboratory abnormality and a medically confirmed diagnosis A reporter, a product, a treatment indication and a documented treatment failure

Question 9 of 10 A product complaint reports a defective package but contains no patient, exposure or clinical event information. How should it generally be handled?

As an ICSR with a reaction of product complaint As a quality-related matter, while assessing whether any associated patient event requires separate PV processing As an ICSR because every product complaint is a safety report By coding an anticipated adverse reaction associated with the defect

Question 10 of 10 Which practice would present the greatest inspection concern in handling borderline reports?

Using a controlled decision tree and documenting the basis for validity decisions Escalating selected cases for medical review under defined criteria Being unable to explain why a database case was considered valid or why a report was not processed as a valid ICSR Sampling invalid and borderline reports for quality control

GVP Module VI: Difficult ICSR Validity and Assessment Scenarios

Cookie Settings